Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
20031.2k citationsDavid G. Pfister, David H. Johnson et al.Journal of Clinical Oncologyprofile →
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009752 citationsChristopher G. Azzoli, Sherman Baker et al.Journal of Clinical Oncologyprofile →
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015695 citationsGregory A. Masters, Sarah Temin et al.Journal of Clinical Oncologyprofile →
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
2011399 citationsVicki L. Keedy, Sarah Temin et al.Journal of Clinical Oncologyprofile →
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
2017235 citationsMark G. Kris, Laurie E. Gaspar et al.Journal of Clinical Oncologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by John R. Strawn
Since
Specialization
Citations
This map shows the geographic impact of John R. Strawn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Strawn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Strawn more than expected).
This network shows the impact of papers produced by John R. Strawn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Strawn. The network helps show where John R. Strawn may publish in the future.
Co-authorship network of co-authors of John R. Strawn
This figure shows the co-authorship network connecting the top 25 collaborators of John R. Strawn.
A scholar is included among the top collaborators of John R. Strawn based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with John R. Strawn. John R. Strawn is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
11 of 11 papers shown
1.
Kris, Mark G., Laurie E. Gaspar, Jamie E. Chaft, et al.. (2017). Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. Journal of Clinical Oncology. 35(25). 2960–2974.235 indexed citations breakdown →
2.
Masters, Gregory A., Sarah Temin, Christopher G. Azzoli, et al.. (2015). Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 33(30). 3488–3515.695 indexed citations breakdown →
Keedy, Vicki L., Sarah Temin, Mark R. Somerfield, et al.. (2011). American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology. 29(15). 2121–2127.399 indexed citations breakdown →
Azzoli, Christopher G., Sherman Baker, Sarah Temin, et al.. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(36). 6251–6266.752 indexed citations breakdown →
Pfister, David G., David H. Johnson, Christopher G. Azzoli, et al.. (2003). American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003. Journal of Clinical Oncology. 22(2). 330–353.1169 indexed citations breakdown →
Dennis, Evan, John H. Moyer, & John R. Strawn. (1956). Laboratory observations on chlorisondamine (ecolid) and clinical results when used for the treatment of hypertension.. PubMed. 7(11). 1765–75.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.